Researchers at the University of California San Diego have demonstrated that immunity to cytomegalovirus (CMV), a common virus, can be leveraged to leisurely the growth of pancreatic tumors in mice. The study, published this week, offers a novel approach to combating a cancer known for its aggressive nature and limited treatment options.
The research, detailed in findings released Tuesday, centers on the ability to redirect the immune system’s response to CMV – a virus that infects approximately half of the adult population – to recognize and attack pancreatic cancer cells. Traditionally, pancreatic tumors have proven difficult for the immune system to identify, largely because cancer cells lack distinctive markers that signal an immune response. The UC San Diego team discovered a way to make these tumors “visible” to immune cells.
The La Jolla Institute for Immunology contributed to the research, focusing on enhancing the ability of immune cells to infiltrate and target the tumors. According to reports, the team successfully stimulated an immune response against the cancer cells in the mice, resulting in a measurable slowing of tumor growth. The study builds on previous work identifying specific immune cells that can recognize and respond to pancreatic cancer, but had previously been unable to effectively reach the tumor site.
Inside Precision Medicine reported that the research suggests a potential therapeutic strategy involving harnessing existing immunity to CMV, rather than developing entirely recent immune therapies. This approach could potentially reduce the time and cost associated with developing cancer treatments. The researchers emphasize that this is a preclinical study, and further research is needed to determine if the findings translate to humans.
The study’s success hinges on the ability to redirect the immune system’s existing response to CMV. The virus triggers a robust immune response, and researchers found a way to adapt that response to target the pancreatic cancer cells. The precise mechanisms by which this redirection occurs are still under investigation, but the initial results are promising.
Researchers are now planning further studies to refine the approach and assess its safety and efficacy in larger animal models. No timeline has been announced for potential human clinical trials. The UC San Diego team has not yet commented on potential partnerships with pharmaceutical companies to advance the research.
